Skip to main content
Fig. 7 | Biomarker Research

Fig. 7

From: Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling

Fig. 7

Crizotinib combined with IN10018 exhibited a synergistic effect in human TNBC organoids. A Steps for constructing TNBC organoids. B H&E staining and immunohistochemistry of TNBC tissues and organoids. C Bright-field images of TNBC organoids after being treated with IN10018, crizotinib, or combination therapy. Scale bar, 50 µm. D Quantification of organoid proliferation by CellTiter-Glo assay. E, F The cell viability and IC50 of TNBC organoids. G Survival curves of TNBC organoids. The concentration ratio of IN10018 and Crizotinib is 2:1. H The CI values of TNBC organoids. Data are represented as mean ± SEM. Significant levels: ns = not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us